• Cancer drug margins: Dr. Ajaikumar refuted claims of excessive markups on cancer medicines, stating that margins on essential drugs like cisplatin and Taxol are under 10% to 15%. He added that strict DPCO price caps have rendered several essential drugs loss-making, leading pharmaceutical companies to halt production and create supply shortages.
• HCG business impact: Management stated that the Supreme Court's scrutiny and negative market sentiment will not impact HCG's performance, as the hospital does not operate on inflated markups and maintains an overall margin of around 18%.
• Healthcare cost comparison: Medical care in India is significantly cheaper than in developed nations—such as PET scans costing $200 to $250 in India compared to $3,500 in the US—while matching global clinical outcomes and quality standards.
• Hospital price regulation: Management pushed back against proposed caps on hospital margins and room rents driven by PILs, cautioning that misinformed price controls risk lowering quality of care and causing disease recurrences.